Improving care delivery for patients with Alcohol Related Liver Disease (ARLD) in the North West region of England
Date: 26 June 2017
Alcoholic liver disease accounts for over a third (37%) of liver-disease deaths1 . A 2013 NCEPOD review indicated gaps in quality of care for this cohort of patients, identifying a lack of specialist input and inconsistent standards of care3.
Both the NCEPOD3 report and NICE guidance2 recommend offering thiamine to patients at risk of malnutrition and other alcohol related liver disease (ARLD) related conditions. Pabrinex contains water soluble vitamins, specifically vitamins B (thiamine, riboflavin, nicotinamide and pyridoxine) and C (ascorbic acid). As these vitamins are not produced by the body, it is essential to ensure they are replaced3. Intravenous Pabrinex administered within 6 hours of hospital arrival is included within the AQ ARLD measure set.
This analysis looks at patients treated against the AQ measure set with further review of ARLD-04: IV Pabrinex administered within 6 hours of hospital arrival.